BRCA1 and breast cancer: In contrast, in other systems, it has been shown that PARP inhibitors, together with IR, have very good effects such as in BRCA1(+/−) lymphoblastoid cells, hepatocellular cancer and lung and breast cancer xenografts [60,61,62].